What is Lifesci Capital's Forecast for CLDX Q2 Earnings?

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Lifesci Capital issued their Q2 2025 earnings estimates for Celldex Therapeutics in a report issued on Friday, June 13th. Lifesci Capital analyst S. Slutsky anticipates that the biopharmaceutical company will post earnings per share of ($0.85) for the quarter. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.48) per share. Lifesci Capital also issued estimates for Celldex Therapeutics' Q3 2025 earnings at ($0.88) EPS and Q4 2025 earnings at ($0.90) EPS.

CLDX has been the topic of several other research reports. HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Celldex Therapeutics in a research report on Friday, June 13th. Canaccord Genuity Group began coverage on Celldex Therapeutics in a research note on Monday, April 28th. They set a "buy" rating and a $64.00 target price on the stock. The Goldman Sachs Group cut their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. UBS Group decreased their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Morgan Stanley lowered their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $50.11.

Celldex Therapeutics Trading Up 3.8%

Shares of CLDX stock traded up $0.76 during trading on Monday, hitting $20.82. The company's stock had a trading volume of 724,877 shares, compared to its average volume of 940,207. The company has a market cap of $1.38 billion, a PE ratio of -7.71 and a beta of 1.33. The business has a fifty day moving average of $19.70 and a 200-day moving average of $21.64. Celldex Therapeutics has a 52 week low of $14.40 and a 52 week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 2,366.07% and a negative return on equity of 23.46%. The firm had revenue of $0.70 million during the quarter, compared to analysts' expectations of $1.08 million.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC increased its stake in shares of Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 878 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Celldex Therapeutics by 6,665.9% during the 1st quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company's stock valued at $54,000 after buying an additional 2,933 shares in the last quarter. Headlands Technologies LLC bought a new position in Celldex Therapeutics in the 4th quarter worth approximately $81,000. AlphaQuest LLC boosted its holdings in Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after buying an additional 2,705 shares during the period. Finally, Aquatic Capital Management LLC purchased a new position in Celldex Therapeutics in the 4th quarter valued at approximately $121,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.